Amicus Therapeutics (FOLD)
Market Price (4/28/2026): $14.5 | Market Cap: $4.5 BilSector: Health Care | Industry: Biotechnology
Amicus Therapeutics (FOLD)
Market Price (4/28/2026): $14.5Market Cap: $4.5 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Low stock price volatilityVol 12M is 45% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Trading close to highsDist 52W High is 0.0%, Dist 3Y High is -0.2% Weak multi-year price returns2Y Excs Rtn is -9.3%, 3Y Excs Rtn is -48% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 97x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 135x Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 74% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.5% Key risksFOLD key risks include [1] heavy reliance on its key therapy Galafold and a limited pipeline, Show more. |
| Low stock price volatilityVol 12M is 45% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Trading close to highsDist 52W High is 0.0%, Dist 3Y High is -0.2% |
| Weak multi-year price returns2Y Excs Rtn is -9.3%, 3Y Excs Rtn is -48% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 97x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 135x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 74% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.5% |
| Key risksFOLD key risks include [1] heavy reliance on its key therapy Galafold and a limited pipeline, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Amicus Therapeutics (FOLD) stock has remained largely at the same level since 12/31/2025 because of the following key factors:
1. Proposed Acquisition by BioMarin Pharmaceutical created a price ceiling.
In December 2025, BioMarin Pharmaceutical entered a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in cash, totaling $4.8 billion. This proposed acquisition, expected to close in the second quarter of 2026, has effectively capped Amicus's stock price, as the market has largely factored in this offer, leading to the stock trading consistently near the acquisition price.
2. Mixed Q4 2025 earnings report balanced investor sentiment.
Amicus Therapeutics reported Q4 2025 earnings on February 20, 2026, which presented a mixed financial picture. The company missed analysts' consensus earnings per share (EPS) estimate by $0.03, reporting an adjusted EPS of $0.10 against an expectation of $0.13. Conversely, quarterly revenue exceeded estimates, rising 23.7% year-over-year to $185.21 million, surpassing analyst projections of $180 million to $185 million. This combination of an EPS miss and a revenue beat likely contributed to a balanced market reaction, preventing significant price swings.
Show more
1. Proposed Acquisition by BioMarin Pharmaceutical created a price ceiling.
In December 2025, BioMarin Pharmaceutical entered a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in cash, totaling $4.8 billion. This proposed acquisition, expected to close in the second quarter of 2026, has effectively capped Amicus's stock price, as the market has largely factored in this offer, leading to the stock trading consistently near the acquisition price.
2. Mixed Q4 2025 earnings report balanced investor sentiment.
Amicus Therapeutics reported Q4 2025 earnings on February 20, 2026, which presented a mixed financial picture. The company missed analysts' consensus earnings per share (EPS) estimate by $0.03, reporting an adjusted EPS of $0.10 against an expectation of $0.13. Conversely, quarterly revenue exceeded estimates, rising 23.7% year-over-year to $185.21 million, surpassing analyst projections of $180 million to $185 million. This combination of an EPS miss and a revenue beat likely contributed to a balanced market reaction, preventing significant price swings.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
12/31/2025 to 4/27/2026| Return | Correlation | |
|---|---|---|
| FOLD | 1.8% | |
| Market (SPY) | 4.2% | -0.1% |
| Sector (XLV) | -7.3% | 30.6% |
Fundamental Drivers
nullnull
Market Drivers
9/30/2025 to 4/27/2026| Return | Correlation | |
|---|---|---|
| FOLD | 83.9% | |
| Market (SPY) | 7.0% | 12.6% |
| Sector (XLV) | 3.5% | 12.4% |
Fundamental Drivers
nullnull
Market Drivers
3/31/2025 to 4/27/2026| Return | Correlation | |
|---|---|---|
| FOLD | 77.6% | |
| Market (SPY) | 28.1% | 24.1% |
| Sector (XLV) | -0.4% | 37.2% |
Fundamental Drivers
nullnull
Market Drivers
3/31/2023 to 4/27/2026| Return | Correlation | |
|---|---|---|
| FOLD | 30.7% | |
| Market (SPY) | 79.8% | 26.9% |
| Sector (XLV) | 16.0% | 32.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| FOLD Return | -50% | 6% | 16% | -34% | 51% | 2% | -37% |
| Peers Return | 2% | 29% | 2% | -1% | -0% | -9% | 21% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 5% | 91% |
Monthly Win Rates [3] | |||||||
| FOLD Win Rate | 42% | 50% | 58% | 42% | 58% | 100% | |
| Peers Win Rate | 52% | 65% | 52% | 47% | 55% | 25% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| FOLD Max Drawdown | -62% | -46% | -18% | -36% | -40% | 0% | |
| Peers Max Drawdown | -23% | -18% | -24% | -17% | -32% | -14% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BMRN, SRPT, VRTX, REGN, ALNY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/27/2026 (YTD)
How Low Can It Go
| Event | FOLD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -73.9% | -25.4% |
| % Gain to Breakeven | 283.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -40.6% | -33.9% |
| % Gain to Breakeven | 68.3% | 51.3% |
| Time to Breakeven | 36 days | 148 days |
| 2018 Correction | ||
| % Loss | -56.3% | -19.8% |
| % Gain to Breakeven | 128.9% | 24.7% |
| Time to Breakeven | 373 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -81.4% | -56.8% |
| % Gain to Breakeven | 436.9% | 131.3% |
| Time to Breakeven | 2,074 days | 1,480 days |
Compare to BMRN, SRPT, VRTX, REGN, ALNY
In The Past
Amicus Therapeutics's stock fell -73.9% during the 2022 Inflation Shock from a high on 1/7/2021. A -73.9% loss requires a 283.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Amicus Therapeutics (FOLD)
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
AI Analysis | Feedback
Here are 1-3 brief analogies for Amicus Therapeutics (FOLD):
- Like BioMarin Pharmaceutical (BMRN) but focused on a different set of rare genetic diseases.
- Similar to Ultragenyx Pharmaceutical (RARE), developing treatments for specific rare genetic conditions.
- A specialized biotech company akin to Sarepta Therapeutics (SRPT), but targeting different rare genetic disorders.
AI Analysis | Feedback
- Galafold: An oral precision medicine for the treatment of adults with Fabry disease.
- AT-GAA: A novel treatment paradigm for Pompe disease.
- CLN3 (AT-GTX-502): A gene therapy in clinical study for CLN3 disease.
- CDKL5: A gene therapy candidate for CDKL5 deficiency disorder.
AI Analysis | Feedback
Amicus Therapeutics (symbol: FOLD) is a biotechnology company that develops and delivers medicines for rare diseases. Based on the nature of its products (prescription medicines like Galafold for Fabry disease), Amicus Therapeutics primarily sells its products to other companies and organizations within the healthcare system, rather than directly to individual patients.
The major categories of customers for Amicus Therapeutics include:
- Pharmaceutical Wholesalers and Distributors: These companies purchase medicines in bulk from manufacturers like Amicus Therapeutics and then distribute them to pharmacies, hospitals, and other healthcare providers.
- Hospitals and Clinics: Healthcare institutions, including specialized rare disease centers, that purchase and administer Amicus Therapeutics' medicines to their patients.
- Specialty Pharmacies: Pharmacies that specialize in dispensing complex, high-cost, or rare disease medications, often providing additional support services to patients and healthcare providers.
AI Analysis | Feedback
```html- Lonza Group AG (LONS.SW)
- AGC Biologics
- Almac Group
- Nationwide Children's Hospital
AI Analysis | Feedback
Bradley L. Campbell, President and Chief Executive Officer
Bradley L. Campbell became the Chief Executive Officer of Amicus Therapeutics in 2022, having joined the company in 2006. He previously served as Chief Operating Officer and led the global commercialization of Galafold, Amicus's first approved medicine. Prior to his tenure at Amicus, he gained experience in commercial and business development roles at Genzyme and Bristol-Myers Squibb, and as a strategy consultant for Marakon Associates, bringing over 20 years of experience in the orphan drug industry. Mr. Campbell also served on the board of Progenics Pharmaceuticals from 2016 until its acquisition by Lantheus Holdings in 2020.
Simon Harford, Chief Financial Officer
Simon Harford serves as the Chief Financial Officer for Amicus Therapeutics.
David Clark, Chief People Officer
David Clark holds the position of Chief People Officer at Amicus Therapeutics.
Jeffrey P. Castelli, PhD, Chief Development Officer
Jeffrey P. Castelli, PhD, is the Chief Development Officer for Amicus Therapeutics. In 2019, he was also mentioned as Chief Portfolio Officer and Head of Gene Therapy.
Ellen S. Rosenberg, Chief Legal Officer, General Counsel and Corporate Secretary
Ellen S. Rosenberg is the Chief Legal Officer, General Counsel, and Corporate Secretary at Amicus Therapeutics.
AI Analysis | Feedback
Key Risks to Amicus Therapeutics (FOLD)
Amicus Therapeutics (FOLD), a biotechnology company specializing in medicines for rare diseases, faces several key risks inherent to the pharmaceutical and biotechnology industry, particularly concerning its commercial products and pipeline development.
- Risk of Acquisition by BioMarin and its Implications: The proposed $4.7 billion acquisition by BioMarin Pharmaceutical represents a significant and immediate risk to the existing structure and future trajectory of Amicus Therapeutics. While the acquisition may offer a premium to shareholders, it introduces substantial integration risks, potential rationalization of Amicus's standalone pipeline, and a dilution of its unique identity within a larger corporate entity. Should the acquisition not proceed, Amicus would then continue to navigate its business as an independent entity, facing the other inherent risks more directly.
- Competition and Patent Risk for Commercial Products: Amicus Therapeutics is heavily reliant on its commercial products, primarily Galafold for Fabry disease and its treatments for Pompe disease, for revenue generation. The company faces ongoing patent litigation for Galafold, including a notable challenge from Aurobindo and an expected decision by mid-2026 on a Teva patent challenge, which could impact its market exclusivity. Furthermore, Amicus confronts significant competition from established pharmaceutical and biotechnology companies such as Takeda, Sanofi, and Chiesi in the Fabry and Pompe disease markets. The potential emergence of newer therapeutic approaches, including advanced gene editing and biologics, could also challenge the market position of Amicus's current small-molecule drugs and potentially curative gene therapies, thereby reducing demand for chronic treatments.
- Clinical Development and Regulatory Approval Risk for Pipeline Products: A critical risk for Amicus Therapeutics is the successful clinical development and regulatory approval of its pipeline candidates, such as DMX-200 for FSGS and its gene therapy programs. There is no guarantee that ongoing or future clinical trials will demonstrate sufficient efficacy and safety to meet regulatory requirements, or that regulatory bodies will grant market approval even if trial outcomes are positive. Delays or setbacks in clinical trials, manufacturing inspections, or the regulatory review process, as previously experienced with AT-GAA, could significantly impede the company's growth prospects and negatively impact its valuation.
AI Analysis | Feedback
nullAI Analysis | Feedback
For Amicus Therapeutics (symbol: FOLD), the addressable markets for their main products or services are as follows:
- Galafold (Fabry disease): The global Fabry disease treatment market size is valued at approximately USD 2.45 billion in 2025 and is projected to increase to about USD 5.20 billion by 2035.
- AT-GAA (Pompe disease): The global Pompe Disease Treatment Market size was valued at USD 2.24 billion in 2024 and is poised to grow from USD 2.4 billion in 2025 to USD 4.09 billion by 2033.
- CLN3 (Batten disease): null
- CDKL5: The global market for CDKL5 Deficiency Disorder (CDD) was valued at US$107.2 million in 2024 and is projected to reach US$130.3 million by 2030.
AI Analysis | Feedback
Expected Revenue Growth Drivers for Amicus Therapeutics (FOLD)
Over the next two to three years, Amicus Therapeutics (FOLD) anticipates several key drivers for its revenue growth:
- Continued Expansion of Galafold (migalastat) for Fabry Disease: Growth is expected from robust new patient starts, sustained commercial execution in existing markets, and expansion into additional geographies. Amicus Therapeutics projected Galafold revenue growth of 10-15% at constant exchange rates (CER) for the full year 2025.
- Accelerated Adoption and Geographic Rollout of Pombiliti + Opfolda (cipaglucosidase alfa + miglustat) for Pompe Disease: This two-component therapy, a relatively recent launch for late-onset Pompe disease, is demonstrating strong momentum. Future revenue is expected from high commercial demand and continued expansion into new launch countries. The company guided for Pombiliti and Opfolda revenue growth of 50-65% at CER for 2025.
- Advancement of Pipeline Asset DMX-200 for Focal Segmental Glomerulosclerosis (FSGS): Although commercialization may extend beyond the immediate two-to-three-year window, the progression of DMX-200, currently in a Phase 3 clinical study, is a significant long-term driver of potential revenue. This asset targets a rare kidney disease with no approved therapies, representing a substantial unmet medical need and future market opportunity.
AI Analysis | Feedback
Inbound Investments
- BioMarin Pharmaceutical entered into a definitive agreement in December 2025 to acquire Amicus Therapeutics for approximately $4.8 billion in an all-cash transaction.
- The acquisition valued Amicus Therapeutics at $14.50 per share.
- This acquisition is expected to close in the second quarter of 2026.
Outbound Investments
- Amicus Therapeutics made a $30 million upfront payment for the DMX-200 licensing deal in the first quarter of 2025.
- The company made a recent acquisition of a European biotechnology firm in December 2025.
- Amicus is strategically investing in its pipeline of gene therapies for conditions like Pompe disease and other rare metabolic disorders.
Capital Expenditures
- Capital expenditures for Amicus Therapeutics were -$3.30 million in the last 12 months as of December 31, 2025.
Latest Trefis Analyses
Trade Ideas
Select ideas related to FOLD.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 181.16 |
| Mkt Cap | 25.6 |
| Rev LTM | 3,468 |
| Op Inc LTM | 456 |
| FCF LTM | 591 |
| FCF 3Y Avg | 285 |
| CFO LTM | 676 |
| CFO 3Y Avg | 363 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 14.2% |
| Rev Chg 3Y Avg | 20.0% |
| Rev Chg Q | 13.3% |
| QoQ Delta Rev Chg LTM | 3.2% |
| Op Inc Chg LTM | -4.1% |
| Op Inc Chg 3Y Avg | 100.6% |
| Op Mgn LTM | 13.1% |
| Op Mgn 3Y Avg | 5.4% |
| QoQ Delta Op Mgn LTM | -0.6% |
| CFO/Rev LTM | 19.9% |
| CFO/Rev 3Y Avg | 12.0% |
| FCF/Rev LTM | 17.4% |
| FCF/Rev 3Y Avg | 9.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 25.6 |
| P/S | 6.2 |
| P/Op Inc | 24.5 |
| P/EBIT | 22.1 |
| P/E | 22.2 |
| P/CFO | 22.6 |
| Total Yield | 2.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.0% |
| D/E | 0.0 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -0.0% |
| 3M Rtn | -6.6% |
| 6M Rtn | 1.8% |
| 12M Rtn | 4.5% |
| 3Y Rtn | 9.3% |
| 1M Excs Rtn | -13.9% |
| 3M Excs Rtn | -9.8% |
| 6M Excs Rtn | -6.7% |
| 12M Excs Rtn | -25.1% |
| 3Y Excs Rtn | -63.8% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| BLA761204 | POMBILITI | cipaglucosidase alfa-atga | injectable | 9282023 | 22.4% | -0.7% | -9.7% | -30.5% | 22.2% |
| NDA215211 | OPFOLDA | miglustat | capsule | 9282023 | 22.4% | -0.7% | -9.7% | -30.5% | 22.2% |
| NDA208623 | GALAFOLD | migalastat hydrochloride | capsule | 8102018 | -31.0% | -25.7% | -29.5% | 0.4% | -5.6% |
Price Behavior
Price Behavior
| Market Price | $14.49 | |
| Market Cap ($ Bil) | 4.5 | |
| First Trading Date | 05/31/2007 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $14.40 | $10.84 |
| DMA Trend | up | indeterminate |
| Distance from DMA | 0.6% | 33.7% |
| 3M | 1YR | |
| Volatility | 1.7% | 45.8% |
| Downside Capture | -0.03 | 0.24 |
| Upside Capture | 1.76 | 109.06 |
| Correlation (SPY) | 1.3% | 17.2% |
FOLD Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.02 | -0.02 | -0.01 | 0.59 | 0.63 | 0.78 |
| Up Beta | 0.05 | 0.08 | 0.12 | 1.25 | 0.43 | 0.57 |
| Down Beta | -0.07 | -0.05 | -0.01 | 0.01 | 0.60 | 0.60 |
| Up Capture | 3% | 1% | -1% | 174% | 113% | 93% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 17 | 25 | 59 | 122 | 367 |
| Down Capture | -3% | -6% | -7% | -10% | 71% | 102% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 7 | 14 | 22 | 46 | 106 | 355 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FOLD | |
|---|---|---|---|---|
| FOLD | 98.5% | 45.7% | 1.63 | - |
| Sector ETF (XLV) | 5.9% | 15.8% | 0.17 | 31.9% |
| Equity (SPY) | 31.2% | 12.5% | 1.91 | 17.1% |
| Gold (GLD) | 39.7% | 27.2% | 1.21 | 0.2% |
| Commodities (DBC) | 45.1% | 18.1% | 1.93 | -3.4% |
| Real Estate (VNQ) | 13.1% | 13.4% | 0.67 | 11.7% |
| Bitcoin (BTCUSD) | -17.7% | 42.1% | -0.35 | 8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FOLD | |
|---|---|---|---|---|
| FOLD | 7.8% | 46.9% | 0.32 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 32.7% |
| Equity (SPY) | 12.9% | 17.1% | 0.59 | 34.5% |
| Gold (GLD) | 20.9% | 17.8% | 0.96 | 5.8% |
| Commodities (DBC) | 14.5% | 19.1% | 0.62 | 3.3% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 32.1% |
| Bitcoin (BTCUSD) | 6.5% | 56.3% | 0.33 | 16.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FOLD | |
|---|---|---|---|---|
| FOLD | 6.1% | 55.4% | 0.33 | - |
| Sector ETF (XLV) | 9.1% | 16.5% | 0.45 | 40.8% |
| Equity (SPY) | 14.8% | 17.9% | 0.71 | 40.4% |
| Gold (GLD) | 13.8% | 15.9% | 0.72 | 2.9% |
| Commodities (DBC) | 10.0% | 17.8% | 0.47 | 12.7% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 29.4% |
| Bitcoin (BTCUSD) | 68.2% | 66.9% | 1.07 | 13.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/20/2026 | 0.1% | 0.2% | 0.6% |
| 11/4/2025 | 1.5% | 1.6% | 12.3% |
| 7/31/2025 | -2.3% | 13.1% | 24.8% |
| 5/1/2025 | -13.0% | -20.7% | -21.0% |
| 2/19/2025 | -2.9% | -7.5% | -6.6% |
| 11/6/2024 | -4.3% | -10.6% | -16.9% |
| 8/8/2024 | 13.2% | 15.0% | 16.5% |
| 5/9/2024 | -6.5% | -4.7% | -0.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 11 | 13 |
| # Negative | 13 | 12 | 10 |
| Median Positive | 2.8% | 8.6% | 12.3% |
| Median Negative | -4.0% | -7.8% | -13.4% |
| Max Positive | 13.2% | 22.8% | 34.4% |
| Max Negative | -13.0% | -20.7% | -25.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/20/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 02/19/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Campbell, Bradley L | President and CEO | Direct | Sell | 3042026 | 14.35 | 22,500 | 322,839 | 14,329,460 | Form |
| 2 | Campbell, Bradley L | President and CEO | Direct | Sell | 1222026 | 14.31 | 75,000 | 1,073,182 | 14,612,167 | Form |
| 3 | Clark, David Michael | Chief People Officer | Direct | Sell | 12232025 | 14.17 | 25,642 | 363,380 | 3,481,747 | Form |
| 4 | Campbell, Bradley L | President and CEO | Direct | Sell | 12172025 | 10.86 | 77,926 | 846,011 | 12,265,591 | Form |
| 5 | Clark, David Michael | Chief People Officer | Direct | Sell | 12172025 | 11.00 | 25,643 | 282,073 | 2,984,652 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.